

Leqvio® (Inclisiran)

Policy Number: CS2026D00101Q
Effective Date: June 1, 2026

[↪ Instructions for Use](#)

Table of Contents	Page
Application	1
Coverage Rationale	1
Definitions	3
Applicable Codes	3
Background	3
Clinical Evidence	4
U.S. Food and Drug Administration	5
References	5
Policy History/Revision Information	6
Instructions for Use	7

Commercial Policy
<ul style="list-style-type: none"> Leqvio® (Inclisiran)

Application

This Medical Benefit Drug Policy does not apply to the states listed below; refer to the state-specific policy/guideline, if noted:

State	Policy/Guideline
Arizona	Refer to the state’s Medicaid clinical policy
Florida	Refer to the state’s Medicaid clinical policy
Indiana	Refer to the state’s Medicaid clinical policy
Kansas	Refer to the state’s Medicaid clinical policy
North Carolina	None
Ohio	Leqvio® (Inclisiran) (for Ohio Only)
Pennsylvania	Refer to the state’s Medicaid clinical policy

Coverage Rationale

Leqvio (inclisiran) is proven and medically necessary for the treatment of primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), or clinical atherosclerotic cardiovascular disease (ASCVD) in patients who meet all of the following criteria:

- For **initial therapy**, all of the following:
 - Diagnosis of **one** of the following:
 - Heterozygous familial hypercholesterolemia (HeFH); **or**
 - Atherosclerotic cardiovascular disease (ASCVD) (e.g., acute coronary syndromes, history of myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease presumed to be of atherosclerotic origin); **or**
 - Primary hyperlipidemia
 - and**
 - **One** of the following:
 - Despite adherence to PCSK9 therapy (defined by at least 12 consecutive weeks of use), one of the following:
 - Both of the following:
 - Patient has clinical ASCVD; **and**
 - Patient failed to achieve LDL-C goal of < 55 mg/dL

- **or**
- **Both** of the following:
 - Patient has primary hyperlipidemia (pre-treatment LDL-C \geq 190 mg/dL); **and**
 - Patient failed to achieve LDL-C goal of < 100 mg/dL
- or**
- Patient has a history of intolerance or contraindication to PCSK9 therapy
- and**
- Patient will continue other traditional low-density lipoprotein-cholesterol (LDL-C) lowering therapies (e.g., maximally tolerated statins, ezetimibe) in combination with Leqvio; **and**
- Prescribed by one of the following:
 - Cardiologist
 - Endocrinologist
 - Lipid specialist
- Leqvio will not be used in combination with PCSK9 inhibitor therapy; **and**
- Leqvio dosing is in accordance with the United States Food and Drug Administration approved labeling; **and**
- Initial authorization will be for no more than 12 months
- For **continuation of therapy**, all of the following:
 - Documentation of a positive clinical response to Leqvio therapy; **and**
 - Leqvio will not be used in combination with PCSK9 therapy; **and**
 - Leqvio dosing is in accordance with the United States Food and Drug Administration approved labeling; **and**
 - Reauthorization will be for no more than 12 months

Leqvio (inclisiran) is proven and medically necessary for the treatment of homozygous familial hypercholesterolemia (HoFH) in patients who meet all of the following criteria:

- For **initial therapy**, all of the following:
 - Diagnosis of homozygous familial hypercholesterolemia (HoFH) as confirmed by **one** of the following:
 - Submission of medical records (e.g., chart notes, laboratory values) confirming genetic confirmation of bi-allelic pathogenic/likely pathogenic variants on different chromosomes at the low-density lipoprotein receptor (*LDLR*), apolipoprotein B (*APOB*), proprotein convertase subtilisin kexin type 9 (*PCSK9*), or low-density lipoprotein receptor adaptor protein 1 (*LDLRAP1*) genes or \geq 2 such variants at different loci; **or**
 - Submission of medical records (e.g., chart notes, laboratory values) confirming **both** of the following:
 - Untreated LDL-C greater than 400 mg/dL; **and**
 - **One** of the following:
 - Xanthoma before 10 years of age; **or**
 - Evidence of familial hypercholesterolemia in at least one parent
 - and**
 - Patient is receiving other lipid-lowering therapy (e.g., statin, ezetimibe, LDL apheresis); **and**
 - Submission of medical records (e.g., chart notes, laboratory values) confirming that the patient has a history of failure, contraindication, or intolerance to PCSK9 therapy [e.g., Praluent (alirocumab), Repatha (evolocumab)]; **and**
 - Prescribed by **one** of the following:
 - Cardiologist
 - Endocrinologist
 - Lipid specialist
 - and**
 - Leqvio will not be used in combination with PCSK9 inhibitor therapy [e.g., Praluent (alirocumab), Repatha (evolocumab)] or Juxtapid (lomitapide); **and**
 - Leqvio dosing is in accordance with the United States Food and Drug Administration approved labeling; **and**
 - Initial authorization will be for no more than 12 months
- For **continuation of therapy**, all of the following:
 - Documentation of a positive clinical response to Leqvio therapy; **and**
 - Prescribed by **one** of the following:
 - Cardiologist
 - Endocrinologist
 - Lipid specialist
 - and**
 - Leqvio will not be used in combination with PCSK9 inhibitor therapy [e.g., Praluent (alirocumab), Repatha (evolocumab)] or Juxtapid (lomitapide); **and**
 - Leqvio dosing is in accordance with the United States Food and Drug Administration approved labeling; **and**
 - Reauthorization will be for no more than 12 months

Definitions

High Risk Conditions: Defined as:

- Age ≥ 65 years
- Heterozygous familial hypercholesterolemia
- History of prior coronary artery bypass surgery or percutaneous coronary intervention (PCI) outside of the Major ASCVD Event(s)
- Diabetes mellitus
- Hypertension
- Chronic kidney disease (eGFR 15-59 mL/min/1.73 m²)
- Current smoking
- Persistently elevated LDL-C [LDL-C ≥ 100 mg/dL (≥ 2.6 mmol/L)] despite maximally tolerated statin therapy and ezetimibe
- History of congestive heart failure

Major ASCVD Events: For the purposes of this policy, Major ASCVD Events are defined as:

- Recent acute coronary syndrome (within the past 12 months)
- History of myocardial infarction (other than recent acute coronary syndrome event listed above)
- History of ischemic stroke
- Symptomatic peripheral arterial disease (history of claudication with ankle brachial index < 0.85, or previous revascularization or amputation)

Very High Risk: Defined as a history of multiple Major ASCVD Events or 1 Major ASCVD Event and multiple high-risk conditions.

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

HCPCS Code	Description
J1306	Injection, inclisiran, 1 mg

Diagnosis Code	Description
E75.5	Other lipid storage disorders
E78.00	Pure hypercholesterolemia, unspecified
E78.010	Homozygous familial hypercholesterolemia [HoFH]
E78.011	Heterozygous familial hypercholesterolemia [HeFH]
E78.019	Familial hypercholesterolemia, unspecified
E78.2	Mixed hyperlipidemia
E78.49	Other hyperlipidemia
E78.5	Hyperlipidemia, unspecified
E78.9	Disorder of lipoprotein metabolism, unspecified

Background

Atherosclerosis is an accumulation of lipids [mostly low-density lipoprotein cholesterol (LDL-C)] in the inner lining of the arteries over time. An atherosclerotic cardiovascular event (such as heart attack or stroke) can be caused by an unexpected rupture of the atherosclerotic plaque. Proprotein convertase subtilisin/kexin type 9 (PCSK9), which is synthesized primarily in hepatocytes, enters circulation, and binds to hepatic LDL receptors, targeting the LDL receptors for degradation. In turn, this process reduces the capacity of the liver to bind and remove LDL-C, resulting in increased

LDL-C levels. The binding of PCSK9 by monoclonal antibodies has been shown to reduce LDL-C levels by more than 50%.³⁻⁶

Inclisiran is a cholesterol-lowering double-stranded small interfering ribonucleic acid (siRNA), conjugated on the sense strand with triantennary N-acetylgalactosamine (GalNAc), to facilitate uptake by hepatocytes. Utilizing the RNA interference mechanism, inclisiran directs catalytic breakdown of mRNA in hepatocytes for *PCSK9*. This increases LDL-C receptor recycling and expression, therefore increasing LDL-C uptake and reducing LDL-C levels in circulation.¹

Clinical Evidence

ORION-9 (NCT03397121) was a phase 3, randomized, double blind, placebo-controlled trial that evaluated the use of inclisiran in adult patients with heterozygous familial hypercholesterolemia (HeFH) who have been treated with a maximally tolerated dose of statin therapy. The study randomly assigned in a 1:1 ratio, 242 patients to receive inclisiran and 240 to receive placebo. 25% of patients had preexisting coronary artery disease and 10% had diabetes. The mean baseline LDL-C level was 153.1 mg/dL (\pm 54 mg/dL). 90% of patients were receiving statins, including 75% who were on a high intensity statin. More than 50% were also receiving ezetimibe. The primary end points were the percent change from baseline in the LDL-C level at day 510 and time adjusted percent change from baseline in the LDL-C level between day 90 and day 540. 91.7% of patients in the inclisiran group completed the trial activities through day 540. Secondary endpoints included mean absolute change from baseline in LDL-C at day 510, time-adjusted absolute reduction from baseline between day 90 and day 540, and changes in levels of *PCSK9*, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (HDL) cholesterol. Prespecified exploratory end points included the proportion of patients who met lipid targets for their level of cardiovascular risk and treatment response according to genotype of familial hypercholesterolemia. Study results showed at day 510, the percent change in LDL-C level was a reduction of 39.7% (95% CI -43.7 to -35.7) in the inclisiran group and an increase of 8.2% (95% CI, 4.3 to 12.2) in the placebo group; the between-group difference was -47.9 percentage points (95% CI, -53.5 to -42.3; $p < 0.001$). The time-averaged percent change in the LDL cholesterol level between day 90 and day 540 was a reduction of 38.1% (95% CI, -41.1 to -35.1) in the inclisiran group and an increase of 6.2% (95% CI, 3.3 to 9.2) in the placebo group, for a between-group difference of -44.3 percentage points (95% CI, -48.5 to -40.1; $p < 0.001$). Secondary endpoint analysis showed the mean absolute change from baseline in the LDL-C level at day 510 had a between-group difference of -68.9 mg/dL (95% CI, -77.1 to -60.7; $p < 0.001$). Additionally, the time-averaged observed difference in LDL cholesterol levels between day 90 and day 540 showed a between-group difference of -62.6 mg/dL ($p < 0.001$). At day 510, a reduction from baseline in the mean LDL cholesterol level of 50% or more was reported in 38% of patients in the inclisiran group (compared to 0.8% in the placebo group; $p < 0.001$). 65.3% of patients achieved an LDL-C level of less than 100 mg/dL. The authors concluded that among adults with HeFH, those who received inclisiran had significantly lower levels of LDL-C, than those who received placebo.⁶

Two randomized, double-blind, placebo-controlled, parallel-group phase 3 trials, ORION-10 (NCT03399370) ($n = 1,561$) and ORION-11 (NCT03400800) ($n = 1,617$), were conducted to assess the efficacy, safety, and adverse-event profile of inclisiran over a period of 19 months in patients at high risk for cardiovascular disease in whom LDL-C levels remained elevated, despite use of a maximally tolerated statin therapy with or without additional lipid-lowering therapy. Randomization was stratified according to background use of statins, where patients were assigned 1:1 to receive either inclisiran or placebo on days 1, 90, 270, and 450. The primary endpoints in each trial were placebo-corrected percent change in LDL-C level from baseline to day 510 and time-adjusted percent change in LDL-C level from baseline after day 90 and up to day 540. Secondary endpoints included mean absolute change from baseline in LDL-C at day 510, time-adjusted absolute reduction from baseline between day 90 and day 540, and changes in levels of *PCSK9*, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (HDL) cholesterol. The mean LDL-C level at baseline was 104.7 \pm 38.3 mg/dL (ORION-10) and 105.5 \pm 39.1 mg/dL (ORION-11). Additionally 68% of patients were receiving high-intensity statins. The primary endpoint analysis showed at day 510, inclisiran reduced LDL-C by 52.3% (95% CI, 48.8 to 55.7) in the ORION-10 trial and by 49.9% (95% CI, 46.6 to 53.1) in the ORION-11 trial, with corresponding time-adjusted reductions of 53.8% (95% CI, 51.3 to 56.2) and 49.2% (95% CI, 46.8 to 51.6) ($p < 0.001$ for all comparisons vs placebo). Authors concluded that reductions in LDL-C levels of approximately 50% were obtained with inclisiran, when administered every 6 months.

ORION-13 (NCT04659863) was a 12-month randomized, double-blind, placebo-controlled trial in 13 pediatric patients aged 12 years and older with HoFH and elevated LDL-C. All patients were taking LDL-C-lowering therapies. Patients with a null (negative) variant in both low-density lipoprotein receptor (LDLR) alleles, who were considered unlikely to benefit from a reduction in *PCSK9*, were excluded. The diagnosis of HoFH was made by genetic testing. Patients were randomized in a 2:1 ratio to receive subcutaneous injections of either inclisiran 284 mg ($n = 9$) or placebo ($n = 4$) on Day 1, Day 90, and Day 270. The mean age at baseline was 15 years (range: 12 to 17 years), 69% were female, 85% were White, and 15% were Asian; 8% identified as Hispanic or Latino ethnicity. The mean LDL-C at baseline was 272 mg/dL; all patients were taking statins and 85% were on ezetimibe. The primary efficacy outcome measure was the percent

change from baseline to Day 330 in LDL-C. The difference between the inclisiran and placebo groups in mean percentage change in LDL-C from baseline to Day 330 was -33% (95% CI: -80%, 13%).

Professional Societies

The American College of Cardiology/American Heart Association Task Force published their clinical practice guidelines for the management of blood cholesterol in 2018. With regard to those with severe hypercholesterolemia (LDL-C \geq 190 mg/dL), the guideline recommends:⁵

- In patients 20 to 75 years of age with an LDL-C level of 190 mg/dL or higher (\geq 4.9 mmol/L) maximally tolerated statin therapy is recommended (Level I; B-R).
- In patients 20 to 75 years of age with an LDL-C level of 190 mg/dL or higher (\geq 4.9 mmol/L) who achieve less than a 50% reduction in LDL-C while receiving maximally tolerated statin therapy and/or have an LDL-C level of 100 mg/dL or higher (\geq 2.6 mmol/L) ezetimibe therapy is reasonable (Level IIa; B-R).
- In patients 20 to 75 years of age with a baseline LDL-C level 190 mg/dL or higher (\geq 4.9 mmol/L), who achieve less than a 50% reduction in LDL-C levels and have fasting triglycerides 300 mg/dL or lower (\leq 3.4 mmol/L) while taking maximally tolerated statin and ezetimibe therapy, the addition of a bile acid sequestrant may be considered (Level IIb; B-R).
- In patients 30 to 75 years of age with heterozygous FH and with an LDL-C level of 100 mg/dL or higher (\geq 2.6 mmol/L) while taking maximally tolerated statin and ezetimibe therapy, the addition of a PCSK9 inhibitor may be considered (Level IIb; B-R).
- In patients 40 to 75 years of age with a baseline LDL-C level of 220 mg/dL or higher (\geq 5.7 mmol/L) and who achieve an on-treatment LDL-C level of 130 mg/dL or higher (\geq 3.4 mmol/L) while receiving maximally tolerated statin and ezetimibe therapy, the addition of a PCSK9 inhibitor may be considered (Level IIb; C-LD).

U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Leqvio is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, adults and pediatric patients aged 12 years and older with heterozygous familial hypercholesterolemia (HeFH), and pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH).

References

1. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a Hugu prevalence review. *American journal of epidemiology*. 2004;160:407-420.
2. Banerjee Y, Shah K, Al-Rasadi K. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. *n Engl J Med*. 2012;366(25):2425-2426.
3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
4. Haase A, Goldberg AC. Identification of people with heterozygous familial hypercholesterolemia. *Current opinion in lipidology*. 2012;23:282-289.
5. Leqvio [package insert]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation; February 2026.
6. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. *European heart journal*. 2013;34:3478-3490a.
7. Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. *n Engl J Med*. 2020;382(16):1520-1530.
8. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. *n Engl J Med*. 2017;376(15):1430-1440.
9. Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. *n Engl J Med*. 2020;382(16):1507-1519.

10. Writing Committee, Lloyd-Jones DM, Morris PB, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol.* 2022;80(14):1366-1418. doi:10.1016/j.jacc.2022.07.006.
11. Cuchel M, Raal FJ, Hegele RA, et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. *Eur Heart J.* 2023;44(25):2277-2291. doi:10.1093/eurheartj/ehad197.

Policy History/Revision Information

Date	Summary of Changes
06/01/2026	<p>Coverage Rationale</p> <ul style="list-style-type: none"> ● Added language to indicate Leqvio (inclisiran) is proven and medically necessary for the treatment of homozygous familial hypercholesterolemia (HoFH) in patients who meet all of the following criteria: <p>Initial Therapy</p> <ul style="list-style-type: none"> ○ Diagnosis of homozygous familial hypercholesterolemia (HoFH) as confirmed by one of the following: <ul style="list-style-type: none"> ▪ Submission of medical records (e.g., chart notes, laboratory values) confirming genetic confirmation of bi-allelic pathogenic/likely pathogenic variants on different chromosomes at the low-density lipoprotein receptor (<i>LDLR</i>), apolipoprotein B (<i>APOB</i>), proprotein convertase subtilisin kexin type 9 (<i>PCSK9</i>), or low-density lipoprotein receptor adaptor protein 1 (<i>LDLRAP1</i>) genes or ≥ 2 such variants at different loci ▪ Submission of medical records (e.g., chart notes, laboratory values) confirming both of the following: <ul style="list-style-type: none"> – Untreated LDL-C greater than 400 mg/dL – One of the following: <ul style="list-style-type: none"> ● Xanthoma before 10 years of age ● Evidence of familial hypercholesterolemia in at least one parent ○ Patient is receiving other lipid-lowering therapy (e.g., statin, ezetimibe, LDL apheresis) ○ Submission of medical records (e.g., chart notes, laboratory values) confirming that the patient has a history of failure, contraindication, or intolerance to PCSK9 therapy [e.g., Praluent (alirocumab), Repatha (evolocumab)] ○ Prescribed by one of the following: <ul style="list-style-type: none"> ▪ Cardiologist ▪ Endocrinologist ▪ Lipid specialist ○ Leqvio will not be used in combination with PCSK9 inhibitor therapy [e.g., Praluent (alirocumab), Repatha (evolocumab)] or Juxtapid (lomitapide) ○ Leqvio dosing is in accordance with the U.S. FDA approved labeling ○ Initial authorization will be for no more than 12 months <p>Continuation of Therapy</p> <ul style="list-style-type: none"> ○ Documentation of a positive clinical response to Leqvio therapy ○ Prescribed by one of the following: <ul style="list-style-type: none"> ▪ Cardiologist ▪ Endocrinologist ▪ Lipid specialist ○ Leqvio will not be used in combination with PCSK9 inhibitor therapy [e.g., Praluent (alirocumab), Repatha (evolocumab)] or Juxtapid (lomitapide) ○ Leqvio dosing is in accordance with the U.S. FDA approved labeling ○ Reauthorization will be for no more than 12 months <p>Supporting Information</p> <ul style="list-style-type: none"> ● Updated <i>Clinical Evidence</i>, <i>FDA</i>, and <i>References</i> sections to reflect the most current information ● Archived previous policy version CS2026D00101P

Instructions for Use

This Medical Benefit Drug Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state or contractual requirements for benefit plan coverage govern. Before using this policy, check the federal, state or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Benefit Drug Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the InterQual[®] criteria, to assist us in administering health benefits. The UnitedHealthcare Medical Benefit Drug Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.